1. Case presented by Dr Polkinghorn
65 yo woman with obstructive colon CA  emergency diverting colostomy
7/2009: Found to have synch but isolated liver mets
FOLFOX/bevacizumab with significant response  some RFA of liver mets + reversal of colostomy
Postoperative complications (liver abscess requiring drainage)
? Recurrent vs residual lesion in liver
After healing, restarted on capecitabine/bevacizumab

2. Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Allegra CJ et al.
J Clin Oncol 2011; 1(29); 11-16
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
Eric Van Cutsem et al.
J Clin Oncol 2011; 1(29); 1-4

3. AVANT: Results from a Randomized, Three-Arm Multinational Phase III Study to Investigate Bevacizumab with Either XELOX or FOLFOX4 vs FOLFOX4 Alone as Adjuvant Treatment for Colon Cancer
De Gramont A et al. Proc GI Cancers Symposium 2011;Abstract 362.

4. Case presented by Dr Polkinghorn
65 yo woman with obstructive colon CA  emergency diverting colostomy
7/2009: Found to have synch but isolated liver mets
FOLFOX/bevacizumab with significant response  some RFA of liver mets + reversal of colostomy
Postoperative complications (liver abscess requiring drainage)
? Recurrent vs residual lesion in liver
After healing, restarted on capecitabine/bevacizumab 4